As Janssen celebrated the FDA approval of the first novel therapy for depression in three decades with Spravato, Allergan released new, but unfortunately disappointing Phase 3 data for its own therapy rapastinel, confirming that it failed to outperform placebo in the treatment of major depressive disorder (MDD).
Ook interessant voor je
